Sanara MedTech Inc. (NASDAQ:SMTI) Receives $34.00 Average PT from Analysts

Sanara MedTech Inc. (NASDAQ:SMTI) has been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $34.00.

SMTI has been the topic of several recent research reports. Zacks Research raised Sanara MedTech from a “strong sell” rating to a “hold” rating in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research report on Tuesday, April 21st. Lake Street Capital began coverage on Sanara MedTech in a research report on Wednesday, April 15th. They issued a “buy” rating and a $32.00 target price on the stock. Wall Street Zen upgraded Sanara MedTech from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Finally, Freedom Capital raised shares of Sanara MedTech to a “strong-buy” rating in a report on Wednesday, June 17th.

Sanara MedTech Stock Performance

Shares of NASDAQ SMTI opened at $25.00 on Monday. The company has a quick ratio of 2.05, a current ratio of 2.28 and a debt-to-equity ratio of 6.59. The firm’s 50-day moving average price is $22.84 and its two-hundred day moving average price is $21.09. Sanara MedTech has a 52-week low of $16.05 and a 52-week high of $35.95. The stock has a market capitalization of $229 million, a P/E ratio of -6.63 and a beta of 1.18.

Institutional Trading of Sanara MedTech

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its stake in Sanara MedTech by 351.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after purchasing an additional 1,171 shares during the period. Wells Fargo & Company MN increased its stake in shares of Sanara MedTech by 78.1% in the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock valued at $78,000 after purchasing an additional 1,457 shares during the period. Lazard Asset Management LLC increased its stake in shares of Sanara MedTech by 63,100.0% in the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after purchasing an additional 3,155 shares during the period. Deutsche Bank AG raised its holdings in shares of Sanara MedTech by 171.1% during the fourth quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock valued at $93,000 after buying an additional 2,515 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Sanara MedTech by 44.1% during the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after buying an additional 973 shares during the last quarter. 8.10% of the stock is currently owned by institutional investors.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.